Tongxin Zhiyi and Sanbo Brain Hospital Forge Strategic Partnership to Advance Clinical Application of Brain Science Technologies

Recently, Tongxin Zhiyi Technology (Beijing) Co., Ltd. (hereinafter referred to as "Tongxin Zhiyi") and Sanbo Brain Hospital of Capital Medical University (hereinafter referred to as "Sanbo Brain Hospital") have reached a strategic partnership based on the principles of "complementary resource advantages and collaborative innovation between medical institutions and enterprises." The collaboration aims to further strengthen the effective implementation and application of intelligent technologies and products in brain science, create a model for medical-enterprise cooperation to achieve clinical value transformation; help reduce the burden on clinical doctors while improving efficiency, enhance the diagnostic and treatment capabilities for brain diseases, and improve the utilization efficiency of hospital medical resources; and optimize and perfect the entire process of disease treatment for patients with brain disorders. The strategic cooperation agreement was signed within Sanbo Brain Hospital. On the same day, Wang Baoguo, Party Secretary of Sanbo Brain Hospital of Capital Medical University; Zhu Mingwang, Director of the Imaging Department at Sanbo Brain Hospital of Capital Medical University; Xia Bin, Vice President of Sanbo Brain Hospital of Capital Medical University; Liu Weiqi, CEO of Tongxin Zhiyi; and Wang Kai, Operations Director of Tongxin Zhiyi, engaged in friendly exchanges and participated in the signing ceremony for the strategic cooperation.

 Group photo of Tongxin Zhiyi and leaders of Sanbo Brain Hospital (from left: Wang Baoguo, Party Secretary of Sanbo Brain Hospital, Capital Medical University; Zhu Mingwang, Director of the Department of Imaging at Sanbo Brain Hospital, Capital Medical University; Xia Bin, Vice President of Sanbo Brain Hospital, Capital Medical University)

It is understood that Sanbo Brain Hospital, Capital Medical University, is a joint-stock specialized neurological hospital co-founded by a group of renowned domestic neurology experts. According to 2017 statistics from Zhongwei Cloud’s Disease Big Data platform, among the 243 neurological conditions treated at Sanbo Brain Hospital, Capital Medical University, 17 conditions ranked first nationwide in terms of diagnostic and therapeutic capabilities, with more than 4,000 surgeries performed annually.

As a pioneer in the clinical application of intelligent neuroscience products in China, Tongxin Zhiyi has always been guided by the mission to “assist the nation in balancing healthcare supply capacity and promoting the expansion of high-quality medical resources.” With AI-driven neuroscience technology as its foundation, the company addresses the intelligent clinical needs across the entire care continuum for major brain disorders. By deeply integrating expert experience with AI technology, it has developed a series of full-stack, AI-assisted diagnostic and therapeutic solutions for neuroscience that deliver significant clinical value.

 Signing Ceremony Between Tongxin Zhiyi and Sanbo Brain Hospital

This strategic cooperation between Tongxin Zhiyi and Sanbo Brain Hospital serves to enhance the endogenous momentum and innovative vitality of both parties, while also representing a concrete measure to actively build a high-quality and efficient clinical application system for brain science.

This strategic medical-enterprise collaboration aims to address critical industry challenges, including the lack of interpretability in traditional deep learning algorithms, poor model generalizability, and limited clinical adoption of neuroscience technology products. By effectively integrating the hospital’s expert medical resources with the enterprise’s innovative artificial intelligence technologies, and aligning with clinical diagnostic and treatment scenarios as well as the genuine needs of physicians and patients, we will identify disease-associated indicators with true causal relationships. This approach enables stable predictions across varying data distributions. Leveraging Tongxin Zhiyi’s proprietary innovative “Causal Inference + Deep Learning” algorithmic platform, we will tackle diverse neurological disorders. Based on this foundation, we will develop intelligent clinical application products with practical value to assist physicians in diagnosing and treating major brain conditions, such as cerebrovascular diseases, traumatic brain injuries, and brain tumors. Furthermore, we will establish a comprehensive, integrated product and service system for patients, covering the entire continuum of care: screening, diagnosis, treatment, and rehabilitation.

 Signing Ceremony Between Tongxin Zhiyi and Sanbo Brain Hospital

In the future, Tongxin Zhiyi will further strengthen its close collaboration with Sanbo Brain Hospital of Capital Medical University in areas such as technological innovation, interdisciplinary integration, development of distinctive specialties, and talent cultivation. Together, we will conduct frontier research in China’s brain science field and drive major innovations in medical AI products. We are committed to building a leading domestic and world-class public platform for neurological specialty research, clinical practice, and translation of scientific achievements. Additionally, we will establish operational mechanisms that facilitate the expansion of high-quality medical resources, provide physicians with effective clinical decision support, and meet patients’ diverse needs for diagnosis and treatment services. By implementing these initiatives concretely, we aim to significantly improve the efficiency of medical resource utilization and make unremitting efforts to contribute to the “Healthy China” initiative and promote the high-quality development of China’s brain science endeavors.

Sanbo Brain Hospital is a chain medical group specializing in neurology. After nearly 20 years of development, it now operates seven hospitals (including one under construction), covering six provinces and municipalities: Beijing, Chongqing, Hunan, Fujian, Henan, and Yunnan. Its flagship institution is Capital Medical University Sanbo Brain Hospital, an academic medical center integrating clinical care, teaching, and research. It serves as the Eleventh Clinical Medical College and the Third Department of Neurosurgery of Capital Medical University, as well as a National Key Clinical Specialty Construction Unit (Neurosurgery) and a National Training Base for Neurosurgeons. Moving forward, Sanbo will adopt a development model centered on its Beijing brain hospital with nationwide chain operations, aiming to build a first-class brain hospital group in China.

Tongxin Zhiyi—Originating from the Institute for Green Medical Research at Tsinghua University, it is a high-tech enterprise in Tsinghua Science Park and a founding member of the Tsinghua Medical Innovation Alliance (New Medical Alliance). The company maintains long-term, in-depth technical collaborations with the Department of Computer Science and Technology and the Center for Globalization Studies at the School of Economics and Management of Tsinghua University. Leveraging advanced innovations in medical hardware and software, internet technologies, and artificial intelligence (AI), and guided by clinical needs for major diseases such as brain disorders, the company integrates resources across next-generation AI R&D, technology transfer of hardware and software products, and clinical application. This has enabled the creation of a “Next-Generation AI Brain Science Diagnosis and Treatment Platform” that integrates research, production, and application. Its aim is to provide hospitals and physicians with intelligent services covering the entire clinical diagnosis and treatment workflow.